Samsung Bioepis Toasts First Bevacizumab Biosimilar In Korea
Onbevzi Rival To Avastin Launched By Partner Boryung Pharmaceutical
Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.
You may also be interested in...
Celltrion has confirmed that it has now filed its CT-P16 proposed bevacizumab rival to Avastin with the European Medicines Agency, having previously submitted it to regulators in both Korea and the US.
Prescribers must better understand how biosimilars work and why they are safe to use, in order to ensure continued biosimilar uptake, Samsung Bioepis believes.
Samsung Bioepis has seen a positive opinion in the EU for its Byooviz (ranibizumab) biosimilar treatment for wet age-related macular degeneration turned into final approval by the European Commission. The company is also leading the pack in the US.